Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
Status:
Completed
Trial end date:
2016-02-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if study drug (BMS-986020) dose of 600 mg once
daily or 600 mg twice daily for 26 weeks compared with placebo will reduce the decline in
forced vital capacity (FVC) and will be well tolerated in subjects with idiopathic pulmonary
fibrosis (IPF).